Physician profile
Gary Van Ert
NPI 1194894451
$9,949.12
in general payments reported to CMS, 2019-2025
48 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $1,452 · 2021: $1,796 · 2022: $1,487 · 2023: $1,157 · 2024: $965 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.76 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,335.78 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,092.85 | 2019-2025 | Qulipta |
| Novo Nordisk INC | $1,085.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $716.47 | 2019-2022 | |
| Lilly USA, LLC | $688.47 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Glaxosmithkline, LLC. | $528.23 | 2019-2023 | Bexsero, Shingrix |
| Astellas Pharma US INC | $452.91 | 2020-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.03 | 2019-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $333.03 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Pfizer INC. | $332.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.41 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $254.32 | 2021-2025 | |
| Allergan, INC. | $231.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.29 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $200.94 | 2019-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Van Ert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.